Claims for Patent: 7,799,897
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $100
Remove trial restrictions
Summary for Patent: 7,799,897
|Title:||Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis|
|Abstract:||A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.|
|Inventor(s):||Jacob; Gary S. (NY, NY), Nikiforovich; Gregory (St. Louis, MO), Shailubhai; Kunwar (Audubon, PA)|
|Assignee:||Synergy Pharmaceuticals, Inc. (New York, NY)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 7,799,897|
1. A peptide consisting of SEQ ID NO:8, wherein said peptide is a (4,12; 7,15) bicycle and wherein said peptide binds a guanylate cyclase receptor and induces cGMP
2. A pharmaceutical composition in unit dose form comprising a guanylate cyclase receptor agonist peptide consisting of SEQ ID NO:8 and a pharmaceutically acceptable carrier, wherein said peptide is a (4,12; 7,15) bicycle and wherein said peptide binds a guanylate cyclase receptor and induces cGMP production.
3. The pharmaceutical composition of claim 2, wherein the unit dose form is selected from the group consisting of a tablet, a capsule, a solution and an inhalation formulation.
4. The pharmaceutical composition of claim 2, further comprising at least one compound selected from the group consisting of a cGMP-dependent phosphodiesterase inhibitor, an anti-inflammatory agent, an antiviral agent and an anticancer agent.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.